biote Corp. (NASDAQ:BTMD) Short Interest Update

biote Corp. (NASDAQ:BTMD) experienced a notable decline in short interest in November. As of November 30th, the total short interest was 686,700 shares, reflecting a decrease of 16.8% compared to the 825,500 shares reported on November 15th. Currently, 2.3% of the company's shares are sold short, indicating a relatively low level of short selling. With an average daily trading volume of 159,000 shares, the short-interest ratio stands at 4.3 days.

Institutional Investors Update on biote

Recently, institutional investors have adjusted their stake in biote Corp. Notably, Bank of New York Mellon Corp increased its holdings by 59.0% during the second quarter, now owning 94,318 shares valued at approximately $705,000 after acquiring 34,999 additional shares. Bailard Inc. has also entered the scene, acquiring a new stake worth about $146,000 during the same quarter. Allspring Global Investments Holdings LLC made a new investment in biote during the second quarter, valued at around $42,000. Additionally, Skylands Capital LLC raised its stake in biote by 36.2%, increasing its total to 160,845 shares worth $1,202,000 after obtaining 42,729 more shares. Lastly, Rhumbline Advisers boosted its holdings by 104.2%, now owning 28,225 shares valued at $211,000 following an additional purchase of 14,404 shares. Overall, institutional investors currently hold 21.68% of biote's stock.

biote Stock Performance Overview

On Friday, shares of BTMD dipped by $0.17, reaching a price of $6.37. The trading volume for the day was 58,711 shares, which is lower than the average volume of 163,776 shares. Over the past 50 days, the stock has maintained a moving average price of $5.82, while its 200-day moving average price stands at $6.35. The stock’s one-year performance range has seen a low of $3.65 and a high of $8.44. Presently, the company holds a market capitalization of approximately $346.13 million and has a price-to-earnings ratio of 24.50, with a beta value of 1.07.

About biote Corp.

biote Corp. operates within the hormone optimization sector, providing a practice-building platform for physicians and nurse practitioners. The company focuses on training healthcare professionals in bioidentical hormone replacement pellet therapy, aimed at individuals suffering from hormonal imbalances. biote offers the Biote Method, an all-inclusive system that supports Biote-certified practitioners with education, training, certification, practice management software for hormone therapy product management, and digital marketing assistance.

biote, stocks, shortinterest